JP2013533890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533890A5 JP2013533890A5 JP2013519718A JP2013519718A JP2013533890A5 JP 2013533890 A5 JP2013533890 A5 JP 2013533890A5 JP 2013519718 A JP2013519718 A JP 2013519718A JP 2013519718 A JP2013519718 A JP 2013519718A JP 2013533890 A5 JP2013533890 A5 JP 2013533890A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- peptide
- phe
- group
- peptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 14
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 244000137850 Marrubium vulgare Species 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000012875 competitive assay Methods 0.000 claims description 3
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 2
- -1 aromatic amino acid Chemical class 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- DPTMGBIKSPWCNS-VWLOTQADSA-N (2s)-3-phenyl-2-(4-pyren-1-ylbutanoylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)CCCC=1C2=CC=C3C=CC=C4C=CC(C2=C43)=CC=1)C1=CC=CC=C1 DPTMGBIKSPWCNS-VWLOTQADSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36303910P | 2010-07-09 | 2010-07-09 | |
| US61/363,039 | 2010-07-09 | ||
| PCT/US2011/043306 WO2012006497A2 (en) | 2010-07-09 | 2011-07-08 | Mu opioid receptor agonist analogs of the endomorphins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016010055A Division JP6279626B2 (ja) | 2010-07-09 | 2016-01-21 | エンドモルフィンのμオピオイド受容体アゴニスト類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533890A JP2013533890A (ja) | 2013-08-29 |
| JP2013533890A5 true JP2013533890A5 (https=) | 2014-08-28 |
| JP6039553B2 JP6039553B2 (ja) | 2016-12-07 |
Family
ID=45441820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519718A Expired - Fee Related JP6039553B2 (ja) | 2010-07-09 | 2011-07-08 | エンドモルフィンのμオピオイド受容体アゴニスト類似体 |
| JP2016010055A Expired - Fee Related JP6279626B2 (ja) | 2010-07-09 | 2016-01-21 | エンドモルフィンのμオピオイド受容体アゴニスト類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016010055A Expired - Fee Related JP6279626B2 (ja) | 2010-07-09 | 2016-01-21 | エンドモルフィンのμオピオイド受容体アゴニスト類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8716436B2 (https=) |
| EP (2) | EP3246333B1 (https=) |
| JP (2) | JP6039553B2 (https=) |
| CA (1) | CA2810170C (https=) |
| CY (1) | CY1120618T1 (https=) |
| ES (1) | ES2632787T3 (https=) |
| HR (1) | HRP20171119T1 (https=) |
| HU (1) | HUE033875T2 (https=) |
| PL (1) | PL2590992T3 (https=) |
| PT (1) | PT2590992T (https=) |
| RS (1) | RS56129B1 (https=) |
| SI (1) | SI2590992T1 (https=) |
| WO (1) | WO2012006497A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110065648A1 (en) * | 2009-09-15 | 2011-03-17 | Maione Theodore E | Advantageous mu-opiate receptor peptide compounds |
| US20130178427A1 (en) * | 2010-07-09 | 2013-07-11 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| WO2014137496A1 (en) * | 2013-03-08 | 2014-09-12 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| JP2021503481A (ja) * | 2017-11-17 | 2021-02-12 | サイトジェル ファーマ リミテッド ライアビリティ カンパニー | μオピオイド受容体のポリマーアゴニスト |
| AU2018375087B2 (en) * | 2017-11-30 | 2023-10-05 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
| US11578100B2 (en) | 2018-03-28 | 2023-02-14 | Florida Atlantic University Research Corporation | Cyclic peptides, cyclic peptide conjugates and methods of use thereof |
| RU2687740C1 (ru) * | 2018-11-26 | 2019-05-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение пептида Gly-His-Lys-Pro-Gly-Pro для достижения анальгетического эффекта при боли, вызванной температурным раздражением |
| WO2020227134A1 (en) * | 2019-05-03 | 2020-11-12 | The Administrators Of The Tulane Educational Fund | Method for treating opioid use disorder |
| WO2023235232A2 (en) * | 2022-05-31 | 2023-12-07 | The Administrators Of The Tulane Educational Fund | Glycosylated cyclic endomorphin analogs |
| CN116120402B (zh) * | 2022-11-04 | 2024-03-15 | 深圳市维琪科技股份有限公司 | 一种环肽及其组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9203496D0 (sv) * | 1992-11-20 | 1992-11-20 | Kabi Pharmacia Ab | New oligopeptides |
| US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| EP1578786A2 (en) | 2002-12-23 | 2005-09-28 | Janssen Pharmaceutica N.V. | Heteroaryl peptidomimetics as thrombin receptor antagonists |
| US7399762B2 (en) * | 2005-04-25 | 2008-07-15 | Research Triangle Institute | Opioid receptor agonist compounds and their use in treatment of pain |
| US8809278B2 (en) * | 2008-07-11 | 2014-08-19 | University Of Kansas | Cyclic tetrapeptides |
-
2011
- 2011-07-08 PL PL11804387T patent/PL2590992T3/pl unknown
- 2011-07-08 SI SI201131226T patent/SI2590992T1/sl unknown
- 2011-07-08 EP EP17167969.9A patent/EP3246333B1/en not_active Not-in-force
- 2011-07-08 JP JP2013519718A patent/JP6039553B2/ja not_active Expired - Fee Related
- 2011-07-08 HU HUE11804387A patent/HUE033875T2/en unknown
- 2011-07-08 HR HRP20171119TT patent/HRP20171119T1/hr unknown
- 2011-07-08 WO PCT/US2011/043306 patent/WO2012006497A2/en not_active Ceased
- 2011-07-08 ES ES11804387.6T patent/ES2632787T3/es active Active
- 2011-07-08 CA CA2810170A patent/CA2810170C/en not_active Expired - Fee Related
- 2011-07-08 RS RS20170643A patent/RS56129B1/sr unknown
- 2011-07-08 EP EP11804387.6A patent/EP2590992B1/en not_active Not-in-force
- 2011-07-08 PT PT118043876T patent/PT2590992T/pt unknown
-
2012
- 2012-05-22 US US13/477,423 patent/US8716436B2/en active Active
-
2014
- 2014-05-02 US US14/268,057 patent/US20150315238A1/en not_active Abandoned
-
2016
- 2016-01-21 JP JP2016010055A patent/JP6279626B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-03 CY CY171100700T patent/CY1120618T1/el unknown
- 2017-09-14 US US15/704,730 patent/US20180222940A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533890A5 (https=) | ||
| CA2810170C (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| RU2017105115A (ru) | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника | |
| JP2011511778A5 (https=) | ||
| EP2983695B1 (en) | Methods, uses and compositions of tie2 agonists | |
| TR201807309T4 (tr) | Kalp yetmezliği tedavisine yönelik sentetik apelin mimetikleri. | |
| US20240190914A1 (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
| US20160009764A1 (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| US9636378B2 (en) | Methods and compositions for the prevention and treatment neuropathy | |
| CA2550085A1 (en) | Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders | |
| Barlocco et al. | The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics | |
| US10919939B2 (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| US8710184B2 (en) | Motilin-like peptide compound having transmucosal absorbability imparted thereto | |
| AU2011274522B8 (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| CN112203673A (zh) | 混合μ阿片受体和神经肽FF受体结合分子、其制备方法及在治疗中的用途 | |
| WO2014137496A1 (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| HK1246811B (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| HK1180344B (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| HK1221651B (en) | Methods, uses and compositions of tie2 agonists |